Carol J. Levy, MD, CDCES is a Professor in the Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, and in the Department of Obstetrics, Gynecology and Reproductive Science.  She is a board-certified Endocrinologist and Certified Diabetes Educator.  Dr Levy is also the Director of the Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research.  She is an expert in type 1 diabetes and diabetes in pregnancy as well as general endocrinology.  She has over 20 years' experience managing patients with these conditions.

Dr Levy attended medical school with the goal of becoming a physician that she would want to see as a patient.  She believes that Endocrinology is an area where physicians help guide patients on the right path to improve health but the 'ball' is really in the patient's court.  For Dr Levy, the role of the physician to educate and support the patient is of key importance.  During her training at Joslin Clinic, she developed an interest in taking care of pregnant women with diabetes and delighted in the challenge of caring for '2' patients.  She finds general endocrinology both exciting and fascinating as well.  Explaining the reason the thyroid works the way it does, hormonal fluctuations and the impact of this on an individual, and the reasons at times the pancreas (the gland that normally makes insulin) does not, is critical to help people take care of their illnesses.  As a child, she was diagnosed with type 1 diabetes and the patience and respect she received from clinicians along the way (including her obstetrician for her own pregnancies) reinforced her belief that a patient who understands the purpose of a treatment is one who is able to best able to manage his/her disease.

As the Director of the Artificial Pancreas Research Program, she and her team strive to continue to improve the lives and glucose control of people with diabetes by forwarding this technology through both research and clinical care.  This pioneering clinical research program collaborates with multiple researchers both nationally and internationally and has the potential to revolutionize the management of patients with type 1 diabetes.